
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 2, 2010

EZCORP, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)

0-19424
(Commission File Number)

74-2540145
(IRS Employer
Identification No.)

1901 Capital Parkway, Austin, Texas 78746
(Address of principal executive offices) (zip code)

Registrant's telephone number, including area code: **(512) 314-3400**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

- (c) On November 2, 2010, EZCORP, Inc. announced the appointment of Stephen A. Stamp as Senior Vice President and Chief Financial Officer (principal financial officer), effective immediately. A copy of the company's press release announcing this appointment is attached as Exhibit 99.1 and incorporated herein by reference.

Mr. Stamp, age 48, has over 27 years of finance and business experience, having previously served as Chief Financial Officer and Chief Operating Officer of Xanodyne Pharmaceuticals; Group Finance Director at Regus Group PLC; and Group Finance Director at Shire Pharmaceuticals Group PLC. Mr. Stamp's career also includes various roles at Lazard Brothers & Company Ltd. and KPMG. Most recently, Mr. Stamp served as Chief Financial Officer at KV Pharmaceutical Company.

Under the terms of his employment, Mr. Stamp will receive an annual salary of \$350,000, a target bonus of 60% of base salary, and 20,000 restricted shares of EZCORP Class A Non-Voting Common Stock, which will vest pro rata on the first, second and third anniversaries of the date of grant (assuming continued employment). Mr. Stamp will also be eligible for relocation benefits and other benefits typically provided to the company's executive officers. These benefits include a severance plan that provides for salary continuation for a period one year if the company terminates Mr. Stamp's employment without cause.

Item 9.01 Financial Statements and Exhibits.

- (d) Exhibits.

99.1 Press Release, dated November 2, 2010

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EZCORP, INC.

Date: November 2, 2010

By: /s/ Thomas H. Welch, Jr.
Thomas H. Welch, Jr.
Senior Vice President, General Counsel and Secretary

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
99.1	Press Release, dated November 2, 2010



EZCORP ANNOUNCES NEW CHIEF FINANCIAL OFFICER

AUSTIN, Texas (November 2, 2010) — EZCORP, Inc. (Nasdaq: EZPW) announced today the appointment of Stephen A. Stamp as Senior Vice President and Chief Financial Officer.

Mr. Stamp has over 27 years of finance and business experience. Most recently, Mr. Stamp served as Chief Financial Officer at KV Pharmaceutical Company, a U.S. based manufacturer of generic and branded drugs. He previously spent five years at Xanodyne Pharmaceuticals, a U.S. based specialty pharmaceutical company, where he served as Chief Financial Officer and for one year as Chief Operating Officer. Prior to his time at Xanodyne, Mr. Stamp spent over three years as Group Finance Director at Regus Group PLC, a publicly traded, United Kingdom based office services company with operations in over 50 countries; and six years as Group Finance Director at Shire Pharmaceuticals Group PLC, a publicly traded international specialty pharmaceutical company headquartered in the U.K. Mr. Stamp's career also includes various roles at Lazard Brothers & Company Ltd. and KPMG. Mr. Stamp graduated from the University of Manchester with a degree in Business Finance. He is a Chartered Accountant in the U. K.

Paul Rothamel, EZCORP's President and Chief Executive Officer, stated: "Stephen is a seasoned executive who not only brings great finance and accounting experience, but is also a proven business leader well versed in both U.S. and international issues. Stephen has led a variety of finance organizations and has managed numerous complex financing transactions, acquisitions, systems integrations, and cost-containment initiatives. I am excited to add such a successful operational leader and proven strategic thinker to my executive leadership team. His contributions will be invaluable as we continue the strategic growth of EZCORP."

About EZCORP

EZCORP is a leading pawn store operator and provider of specialty consumer financial services. It provides collateralized non-recourse loans, commonly known as pawn loans, and a variety of short-term consumer loans, including payday loans, installment loans and auto title loans, or fee-based credit services to customers seeking loans. At its pawn stores, the company also sells merchandise, primarily collateral forfeited from its pawn lending operations.

EZCORP operates more than 1,000 stores, including more than 500 pawn stores in the U.S. and Mexico and more than 500 short-term consumer loan stores in the U.S. and Canada. The Company also has significant investments in Albemarle & Bond Holdings PLC (ABM.L), one of the U.K.'s largest pawnbroking businesses with over 120 stores, and Cash Converters International Limited (CCV.L and CCV.AUS), which franchises and operates a worldwide network of over 500 stores that provide financial services and sell pre-owned merchandise.

For additional information, contact Investor Relations at (512) 314-2220.